Fundraise

LifeGlue raises €705,000 to make clinical-grade tissue bio-ink

What's the deal? Tampere University spin-out LifeGlue Technologies has raised €705,000 ($777,159) in seed funding, led by InnovestorDealroom has a profile for this one. Try Dealroom → alongside its Angel Cofund and business angels from Finland, Estonia, and Lithuania. The Finnish biotech makes Glue4Life, an animal-free hydrogel and bio-ink that gives cells a structure to grow into tissue such as brain, liver, and nerve.

What's the endgame? LifeGlue does not develop therapies itself; it supplies material to companies and research groups that do. It began commercial operations in December 2024 and has 15 paying customers in Europe, the US, and Australia.

Why now? The round funds production meeting Good Manufacturing Practice (GMP) standards, which customers need before taking tissues made with the material into clinical trials. Unlike the animal-derived gels common today, Glue4Life uses hyaluronic acid with a precisely defined composition, making it easier to approve for human use.

Context: The seed round adds to earlier backing. LifeGlue says it secured more than €1.2 million in non-dilutive research funding before incorporation, won a Business FinlandDealroom has a profile for this one. Try Dealroom → Tempo grant, and in early 2026 drew commitments of up to €200,000 from BSV VenturesDealroom has a profile for this one. Try Dealroom → and up to €150,000 from an EstBANDealroom has a profile for this one. Try Dealroom →-led angel syndicate.

What the investor says: "There are hundreds of companies and research groups in tissue engineering competing to be the first to get their graft to patients. We don't have to guess the winner, because LifeGlue succeeds whenever any of them does," said Janne Juhola, partner at Innovestor.

The signal: The round matters less for its size than for what it represents: a university-born deep-tech venture moving from research toward manufacturing and commercial partnerships. By selling the tools rather than the therapy, LifeGlue bets on the whole tissue-engineering field rather than any single player.

Read more: nordiclifescience.org

Image credit: Generated with Gemini

More top stories